Crossmark

G6PD maintains the VSMC synthetic phenotype and accelerates vascular neointimal hyperplasia by inhibiting the VDAC1–Bax-mediated mitochondrial apoptosis pathway

Crossref DOI link: https://doi.org/10.1186/s11658-024-00566-w

Published Online: 2024-04-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Ting

Cao, Rui-Jie

Niu, Jiang-Ling

Chen, Zhi-Huan

Mu, Shi-Qing

Cao, Tong

Pang, Jie-Xin

Dong, Li-Hua https://orcid.org/0000-0002-4039-963X
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81670394)

Hebei Natural Science Foundation (H202206335)

Hebei Province Central Leading Local Science and Technology Development Fund Project (236Z7707G)
License Information

Text and Data Mining valid from 2024-04-08

Version of Record valid from 2024-04-08
More Information

Article History

Received: 3 January 2024

Accepted: 25 March 2024

First Online: 8 April 2024

Declarations

:

: All animal experiments were conducted in accordance with the Basel Declaration and approved by the Institutional Animal Care and Use Committee of Hebei Medical University (approval number: IACUC-Hebmu-P2023112; approved on 19 April 2023).

: The authors have declared that no conflicts of interest exist.

Document is current

Any future updates will be listed below